Telepsychiatry services for elderly patients may increase access to geriatric specialists, reduce travel time for both providers and patients, and reduce healthcare costs.
The use of a recently developed computerized screening tool, THINC-it, provides both objective and subjective measures of cognitive function in adults with major depressive disorder.
The European Medicine Agency has reported that there may be an association between long-term lithium use and reports of both renal tumors and thyroid cancer.
Researchers aimed to validate sleep deprivation and schizotypy as putative models of psychosis by replicating their effects on cognitive performance.
With the proliferation of online medical information, educators and students alike struggle to discern the legitimacy of “e-health” sources.
Adolescents and young adults who visit emergency departments for psychotic disorder for the first time often do not receive timely follow-up care.
Study demonstrated that the effects of peer victimization on depressive symptoms in adolescent girls were in part due to sleep problems.
The transition from the workforce into retirement is always challenging, but for physicians accustomed to working long or odd hours, it can be especially difficult.
Sandoz and Pear Therapeutics announced that the FDA has granted clearance for reSET-O, the first prescription digital therapeutic for patients with opioid use disorder.
Genetic risk from rare copy number variants and common single-nucleotide polymorphisms may contribute to liability to schizophrenia.
RCADS is often used to measure anxiety and depression and researchers assessed its structural validity for adults, given the life span nature of anxiety.
Investigators examined the efficacy of sertraline and interpersonal psychotherapy vs pill placebo over 12 weeks in woman with postpartum depression.
Lumateperone and follow-on compounds are also being evaluated for bipolar depression, behavioral disturbance associated with dementia, sleep disturbances associated with neuropsychiatric disorders, and other neuropsychiatric conditions including major depressive disorder and autism.
The use of a polygenic risk score for schizophrenia can effectively predict an antipsychotic treatment response after a first episode of psychosis.